C07D263/62

Organic electroluminescence device

The present invention relates to an electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. The present invention also relates to an organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein the light emitting layer contains a metal complex having a group represented by formula (I). ##STR00001##

COMPOUND, MATERIAL FOR AN ORGANIC ELECTROLUMINESCENT DEVICE AND APPLICATION THEREOF

A compound, a material for an organic electroluminescent device and an application thereof are disclosed herein. The compound has a structure represented by Formula (1). The compound has a relatively high refractive index and can effectively improve the light extraction efficiency. The external quantum efficiency of the compound makes it suitable for use as a capping layer when used in an organic electroluminescent device. The compound has a relatively high refractive index in the region of visible light (400-750 nm), which is advantageous for improving the light-emitting efficiency. The compound has a relatively large extinction coefficient in the ultraviolet region (less than 400 nm), which is advantageous for absorbing harmful light and protecting eyesight. Meanwhile, a deuterium atom may be introduced into the compound to significantly improve the device lifetime.

HALOGENATED BENZOXAZINE FOR USE IN THE SYNTHESIS OF POLYBENZOXAZINE
20200087268 · 2020-03-19 ·

A halogenated benzoxazine compound, which can be used in particular as monomer in the synthesis of polybenzoxazine, corresponds to the formula:

##STR00001##

in which: each benzene nucleus of the two oxazine rings bears at least one halogen (represented by the symbol Hal), in particular bromine, chlorine or fluorine; and Z.sub.1 and Z.sub.2, which are identical or different, represent an aliphatic, at least divalent, bonding group comprising at least one carbon atom and optionally at least one heteroatom chosen from O, S, N and P.

HALOGENATED BENZOXAZINE FOR USE IN THE SYNTHESIS OF POLYBENZOXAZINE
20200087268 · 2020-03-19 ·

A halogenated benzoxazine compound, which can be used in particular as monomer in the synthesis of polybenzoxazine, corresponds to the formula:

##STR00001##

in which: each benzene nucleus of the two oxazine rings bears at least one halogen (represented by the symbol Hal), in particular bromine, chlorine or fluorine; and Z.sub.1 and Z.sub.2, which are identical or different, represent an aliphatic, at least divalent, bonding group comprising at least one carbon atom and optionally at least one heteroatom chosen from O, S, N and P.

Organic Electroluminescent Device
20240057469 · 2024-02-15 ·

To provide an organic electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration.

An organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein any one layer of the organic layer contains, for example, as shown below, a metal complex having a group represented by formula (I).

##STR00001##

Organic Electroluminescent Device
20240057469 · 2024-02-15 ·

To provide an organic electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration.

An organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein any one layer of the organic layer contains, for example, as shown below, a metal complex having a group represented by formula (I).

##STR00001##

Organic Electroluminescence Device
20190372030 · 2019-12-05 ·

The present invention relates to an electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. The present invention also relates to an organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein the light emitting layer contains a metal complex having a group represented by formula (I).

##STR00001##

Organic Electroluminescence Device
20190372030 · 2019-12-05 ·

The present invention relates to an electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. The present invention also relates to an organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein the light emitting layer contains a metal complex having a group represented by formula (I).

##STR00001##

Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

Compounds and their use as BACE inhibitors

The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A-related pathologies such as Down's syndrome, -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (mild cognitive impairment), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.